Compare Sermorelin Providers (2026)

Sermorelin is a synthetic 29-amino acid analog of endogenous growth hormone-releasing hormone (GHRH). After subcutaneous injection, it binds to GHRH receptors on somatotroph cells in the anterior pituitary, triggering a pulsatile release of human growth hormone (HGH). That HGH then stimulates the liver to produce IGF-1, the downstream mediator responsible for lean mass accretion, lipolysis, sleep architecture improvement, and cellular repair. Because sermorelin acts upstream of the pituitary rather than bypassing it, the somatostatin feedback axis remains intact. The pituitary self-limits output based on circulating GH levels, which is a meaningful pharmacological distinction from exogenous somatropin.

The primary candidates are adults over 30 with symptomatic age-related growth hormone decline: reduced lean mass, increased visceral adiposity, disrupted slow-wave sleep, low energy, or slow post-exercise recovery. Confirming low or low-normal IGF-1 on a baseline lab draw before starting gives the physician a measurable baseline and avoids treating patients who do not have a deficiency. Sermorelin is contraindicated in patients with active malignancy, known pituitary tumors, proliferative diabetic retinopathy, or carpal tunnel syndrome. Patients on glucocorticoids or thyroid medications may need dose adjustments, as both affect GH axis sensitivity.

Sermorelin is injected subcutaneously, typically into the periumbilical abdomen or lateral thigh. Standard starting doses run 100–200 mcg once daily, administered at bedtime to align with the natural GH pulse that occurs during slow-wave sleep. Physicians titrate upward to 200–300 mcg based on 90-day IGF-1 results and symptom response. At higher doses, many protocols add ipamorelin (a selective ghrelin receptor agonist) or CJC-1295 without DAC to amplify the GH pulse without raising cortisol or prolactin, which are unwanted off-target effects common to older secretagogues like GHRP-6.

Compounded sermorelin through a telehealth provider runs $115–$300 per month for the medication itself. Where that number lands depends on prescribed dose, whether quarterly IGF-1 monitoring is bundled in, and whether the protocol includes combination peptides. Providers like Strut Health and RNK Health bill at the lower end with per-order pricing. bmiMD and Fridays Health sit higher because quarterly labs and physician reviews are built into the plan cost rather than billed separately. Most programs are cash-pay. HSA and FSA funds are accepted by most of the providers reviewed here. Standard health insurance does not cover compounded sermorelin.

The original sermorelin acetate product (Geref, Serono) held FDA approval for growth hormone deficiency in pediatric patients. That product was voluntarily withdrawn from the market in 2008 for commercial rather than safety reasons. Today, sermorelin is prescribed as a compounded formulation under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Compounded sermorelin is not FDA-approved as a finished drug product, but it can be legally prescribed by a licensed physician and dispensed by a state-licensed or FDA-registered sterile compounding pharmacy. Patients should confirm their provider uses a 503A or 503B-registered facility.

Sleep quality and energy are typically the first changes patients report, often within weeks 3–4. Body composition changes take longer: most patients see meaningful reductions in body fat percentage and measurable increases in lean mass between months 3 and 6, which aligns with when IGF-1 levels reach a new steady state. Physicians check IGF-1 at the 90-day mark to assess response and adjust dose. A full 6-month cycle is the clinical standard because sermorelin restores GH secretion gradually through pituitary stimulation rather than delivering exogenous hormone acutely. Results depend on dose adequacy, baseline IGF-1, sleep quality, protein intake, and resistance training volume.

The most common adverse effects are injection site reactions (transient redness, mild induration), flushing, headache, and lightheadedness, all of which are dose-related and most pronounced during the first few weeks of treatment. Water retention and transient joint stiffness occur in some patients at doses above 250 mcg. These generally resolve with dose reduction. Serious adverse events are rare with properly prescribed sermorelin. Because the somatostatin axis remains active, GH oversaturation and the associated risks of exogenous HGH (acromegaly, carpal tunnel syndrome, insulin resistance) are not a clinical concern at therapeutic sermorelin doses. Patients with a personal or family history of thyroid cancer should discuss contraindication risk with their physician before starting.

Synthetic HGH (recombinant somatropin) bypasses the pituitary entirely and delivers growth hormone directly into circulation. It produces faster and larger increases in IGF-1 than sermorelin, which is clinically relevant in severe adult GH deficiency. The tradeoffs are significant: somatropin costs $600–$2,000 per month, requires more precise dosing to avoid supraphysiologic GH levels, and carries higher rates of fluid retention, carpal tunnel syndrome, and insulin resistance. Sermorelin preserves the somatostatin feedback loop, so the pituitary moderates output and physiologic GH levels are less likely to be exceeded. For adults with age-related rather than pathologic GH decline, sermorelin is the more appropriate first-line option. Somatropin is indicated when pituitary function is insufficient to respond to secretagogue stimulation.